MARKET

GNCAQ

GNCAQ

Genocea Biosciences Inc
EXMKT
0.0001
0.0000
0.00%
Closed 16:00 01/30 EST
OPEN
--
PREV CLOSE
0.0001
HIGH
--
LOW
--
VOLUME
--
TURNOVER
--
52 WEEK HIGH
1.480
52 WEEK LOW
0.0001
MARKET CAP
5.88K
P/E (TTM)
-0.0002
1D
5D
1M
3M
1Y
5Y
The Week Ahead In Biotech (June 5-11): Adcom Test For Novavax, ASCO Presentations, Enzo Biochem Earnings And More
Biotech stocks reversed course along with the broader market and closed the week ending June 3 lower. The sector's lean run thus got extended.
Benzinga · 06/05/2022 20:09
Stocks That Hit 52-Week Lows On Tuesday
  On Tuesday, 36 companies achieved new lows for the year.
Benzinga · 05/31/2022 16:06
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Benzinga · 05/31/2022 12:19
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Investor Place · 05/31/2022 11:23
The Week Ahead In Biotech (May 30-June 4): FDA Decision For Eton's Partnered Epilepsy Drug, ASCO Conference Gets Underway And More
Biotech stocks advanced in the week ended May 27, tracking the overall positive sentiment of the broader market. Notwithstanding the week's strength, the sector has been one of the worst performers for the year-to-date period.
Benzinga · 05/30/2022 18:03
20 Stocks Moving in Thursday's Pre-Market Session
Gainers TC Biopharm (Holdings) Plc (NASDAQ: TCBP) shares rose 51.2% to $0.9603 in pre-market trading after dipping 18% on Wednesday.
Benzinga · 05/26/2022 10:46
GRPN, GNCA and LAB among mid-day movers
=Gainers: BlackSky Technology (BKSY) +93%. StoneMor (STON) +51%. Genocea Biosciences (GNCA) +35%. Hoegh LNG Partners (HMLP) +31%. Caleres (CAL) +27%. Evelo Biosciences (EVLO) +20%. Spire Global (SPIR) +17%. Groupon (GRPN)
Seekingalpha · 05/25/2022 16:49
HAPP Stock Soars 38% as Happiness Development Embraces EVs
Investor Place · 05/25/2022 15:03
More
About GNCAQ
Genocea Biosciences, Inc. is a biopharmaceutical company that is engaged in discovering and developing cancer immunotherapies using its Antigen Lead Acquisition System (ATLAS) technology platform. The Company’s Antigen Lead Acquisition System (ATLAS) technology platform allows to identify targets based on each person’s tumor antigen-specific T cell responses. Its programs include GEN-009 is a neoantigen vaccine candidate delivering adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. Its GEN-011 program is an adoptive T cell therapy using neoantigen-targeted peripheral T cells (NPTs). The GEN-011 NPTs is preferred for ATLAS-identified anti-tumor antigens that are used to manufacture a peripheral blood-derived, tumor-specific T cell therapy.

Webull offers kinds of Genocea Biosciences Inc stock information, including EXMKT:GNCAQ real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GNCAQ stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading GNCAQ stock methods without spending real money on the virtual paper trading platform.